Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients

A hard-charging group of Novartis execs have been pouring over the late-stage data they gathered to support their successful campaign to win an FDA approval for Mayzent (siponimod) as a landmark new therapy for multiple sclerosis. And it’s paid off

Crunching the data on their MS drug — tapped as a $1.3 billion blockbuster-in-the-making by Evaluate — researchers concluded that there was clear statistical evidence to show that their drug both preserved the cognitive powers of secondary progressive MS patients treated earlier in the course of their disease as well boosting the ability of patients to think. Patients on their drug beat a control group given a placebo.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 50,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->